| Browse All

Natera, Inc. (NTRA)

Healthcare | Diagnostics & Research | Austin, United States | NasdaqGS
205.42 USD -2.32 (-1.117%) ⇩ (April 21, 2026, 4 p.m. EDT)
After hours: 205.51 +0.09 (0.044%) ⇧ (April 21, 2026, 6:11 p.m. EDT)

Short-term: ★★★★☆ | Long-term: ★★★★☆ | Dividends: ☆☆☆☆☆
Hot Take | April 18, 2026, 10:34 p.m. EDT

Natera represents a strong momentum play fueled by solid revenue growth (39.8%) and a massive short-interest re-rating (up 47%), but the stock is respecting the $203 fifty-day average resistance. The data supports a 'buy on weakness' strategy targeting the $260 call OI wall; the downside case is weak as the massive call OI suggests a floor of $200 where long-only institutional exposure is concentrated.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.148550
AutoARIMA0.153227
AutoETS0.153227
AutoTheta0.190857

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 51%
H-stat 2.18
Ljung-Box p 0.000
Jarque-Bera p 0.036
Excess Kurtosis 0.97
Attribute Value
Sector Healthcare
Revenue per Share 16.867
Market Cap 29,114,433,536
Forward P/E -302.83
Beta 1.68
Profit Margins -9.03%
Website https://www.natera.com

As of April 18, 2026, 10:34 p.m. EDT: Speculative positioning is heavily skewed towards upside calls, with massive open interest walls at $260 and $300+ strikes for the August-November expirations, signaling a bullish conviction in a 15-20%+ move within the next 3-6 months. Heavily skewed 2.61:1 call-to-put ratio suggests traders are pricing in continued clinical validation momentum or resistance breakthrough above $250. Near-term April expiry shows elevated ATM IV on puts relative to calls, hinting at a 'buy the dip' short-covering thesis if support at $190 breaks.


Info Dump

Attribute Value
52 Week Change 0.43645418
Address1 13,011 McCallen Pass
Address2 Building A Suite 100
All Time High 256.36
All Time Low 6.52
Ask 224.62
Ask Size 2
Audit Risk 1
Average Analyst Rating 1.5 - Strong Buy
Average Daily Volume10 Day 1,478,390
Average Daily Volume3 Month 1,218,713
Average Volume 1,218,713
Average Volume10Days 1,478,390
Beta 1.68
Bid 192.55
Bid Size 2
Board Risk 8
Book Value 12.258
City Austin
Compensation As Of Epoch Date 1,735,603,200
Compensation Risk 5
Country United States
Crypto Tradeable 0
Currency USD
Current Price 205.42
Current Ratio 3.393
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 212.77
Day Low 205.205
Display Name Natera
Earnings Call Timestamp End 1,772,141,400
Earnings Call Timestamp Start 1,772,141,400
Earnings Timestamp 1,772,139,600
Earnings Timestamp End 1,778,184,000
Earnings Timestamp Start 1,778,184,000
Ebitda -271,427,008
Ebitda Margins -0.1177
Eps Current Year -1.85382
Eps Forward -0.67834
Eps Trailing Twelve Months -1.52
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 203.2799
Fifty Day Average Change 2.140091
Fifty Day Average Change Percent 0.010527804
Fifty Two Week Change Percent 43.645416
Fifty Two Week High 256.36
Fifty Two Week High Change -50.939987
Fifty Two Week High Change Percent -0.19870491
Fifty Two Week Low 131.811
Fifty Two Week Low Change 73.60899
Fifty Two Week Low Change Percent 0.5584435
Fifty Two Week Range 131.811 - 256.36
Financial Currency USD
First Trade Date Milliseconds 1,435,757,400,000
Float Shares 137,443,880
Forward Eps -0.67834
Forward P E -302.82748
Free Cashflow 141,016,496
Full Exchange Name NasdaqGS
Full Time Employees 6,135
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,775,001,600
Gross Margins 0.64749
Gross Profits 1,493,180,032
Has Pre Post Market Data 1
Held Percent Insiders 0.030650001
Held Percent Institutions 0.94579005
Implied Shares Outstanding 141,731,250
Industry Diagnostics & Research
Industry Disp Diagnostics & Research
Industry Key diagnostics-research
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Long Name Natera, Inc.
Market us_market
Market Cap 29,114,433,536
Market State POST
Max Age 86,400
Message Board Id finmb_27603970
Net Income To Common -208,160,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 29,443,249,875
Number Of Analyst Opinions 19
Open 207.74
Operating Cashflow 215,300,992
Operating Margins -0.13439
Overall Risk 6
Payout Ratio 0.0
Phone 650 980 9190
Post Market Change 0.08999634
Post Market Change Percent 0.043810893
Post Market Price 205.51
Post Market Time 1,776,809,517
Previous Close 207.74
Price Eps Current Year -110.80904
Price Hint 2
Price To Book 16.758036
Price To Sales Trailing12 Months 12.624894
Profit Margins -0.09026
Quick Ratio 3.111
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.45
Region US
Regular Market Change -2.3200073
Regular Market Change Percent -1.1167841
Regular Market Day High 212.77
Regular Market Day Low 205.205
Regular Market Day Range 205.205 - 212.77
Regular Market Open 207.74
Regular Market Previous Close 207.74
Regular Market Price 205.42
Regular Market Time 1,776,801,600
Regular Market Volume 769,898
Return On Assets -0.09544
Return On Equity -0.14317
Revenue Per Share 16.867
Sand P52 Week Change 0.34445214
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 8
Shares Outstanding 141,731,250
Shares Percent Shares Out 0.0343
Shares Short 4,867,085
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 2,990,382
Short Name Natera, Inc.
Short Percent Of Float 0.0358
Short Ratio 3.91
Source Interval 15
State TX
Symbol NTRA
Target High Price 300.0
Target Low Price 190.0
Target Mean Price 257.94736
Target Median Price 260.0
Total Revenue 2,306,113,024
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.52
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 194.73833
Two Hundred Day Average Change 10.681671
Two Hundred Day Average Change Percent 0.054851405
Type Disp Equity
Volume 769,898
Website https://www.natera.com
Zip 78,753